Kornimate/medical-research-clean huggingface dataset:
contrast-induced nephropathy: incidence,risk factors,effective prevention and management method

Conditions: Cardio-Renal Syndrome

Summary: this review article have included about ten thousand patients undergoing percutaneous coronary intervention (pci), aim to identify the incidence of cin in actual, find some new risk factors and the protecting methods for these factors.

about ten thousand patients undergoing percutaneous coronary intervention (pci) from 2010 to 2015 are included in this study. we collect the data about the scr of the patients before and after percutaneous coronary intervention, and define cin as an increase in scr of 0.5 mg/dl or 25% from baseline between 48 and 72 h after contrast medium exposure. besides we obtain the data including clinical characteristics, laboratory data (blood and urine tests) for all the patients. the statistical analysis will find some new risk factors.

Eligibility criteria:
inclusion criteria: 1. congestive heart failure: objective evidences for decreased left ventricular eject fraction (lvef) \<= 50%; 2. moderate to severe chronic kidney disease was defined as an egfr 15 to 59 ml/min per 1.73 m2, calculated via the abbreviated modification of diet in renal disease (mdrd) study equation from scr obtained within 72 hours of enrollment; 3. patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions. exclusion criteria: 1. hemodialysis-dependent patients; 2. complicated with severe short-term progressive disease; 3. patients \< 18 years; 4. pregnancy; 5. emergency cardiac catheterisation (eg, primary percutaneous coronary intervention for st-segment elevation myocardial infarction); 6. exposure to radiographic contrast media within the previous 7 days; 7. acute decompensated heart failure.

Keywords: contrast-induced nephropathy percutaneous coronary intervention risk factors incidence
comparison of outcome of different layers in hypospadias surgery

Conditions: Hypospadias

Summary: to compare the outcome of applying autologous platelet-rich plasma membrane layer and dartos fascial flap versus only dartos fascial flap in mid and distal penile hypospadias surgery. a total of 220 patients fulfilling the selection criteria were admitted after taking informed consent. cases were randomly divided into groups a and b using a random generator of the excel program. in group a, dartos flap and prp sheet layer were applied and in group b, only a preputial dartos fascial flap was applied

objective to compare the outcome of application of autologous platelet-rich plasma membrane layer and dartos fascial flap versus only dartos fascial flap in mid and distal penile hypospadias surgery. methods this randomized controlled trial was conducted at pediatric general surgical department, the children's hospital and the university of child health, lahore for the period of 12 months. non probability, purposive sampling was used for data collection and randomization was done to assign the treatment. total of 220 patients fulfilling the selection criteria were admitted after taking an informed consent. cases were randomly divided into two groups a and b using random generator of excel program. in group-a, dartos flap and prp sheet layer was applied and in group-b, only a preputial dartos fascial flap was applied.

Eligibility criteria:
inclusion criteria: * patients (age 6months to12 years) with mid, distal penile or sub coronal hypospadias having minimal chordae were included in the study exclusion criteria: * patients having proximal hypospadias, moderate to severe chordae, previously operated cases, a preoperative androgens treatment (for example in penoscrotal hypospadias and small sized phallus) were excluded from study

Keywords: hypospadias platelet rich plasma distal penile hypospadias
acute coronary syndrome kcmc

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to develop a quality improvement intervention to address barriers to evidence-based acute coronary syndrome (acs) care in northern tanzania. patients who presented to kilimanjaro christian medical center (kcmc) will be asked to complete a survey about barriers and facilitators of health care. in addition the survey will be administered to all providers, policymakers, and administrators participating in in-depth interviews. data from this survey will be used to develop a quality improvement intervention that will be piloted by kcmc staff. six months after the pilot program is implemented providers, patients, and administrators will be interviewed for their perspectives on the program.


Eligibility criteria:
inclusion criteria: * 18 years or older * symptoms related to acute coronary syndrome * myocardial infarction * clinically sober * able to communicate in swahili or english exclusion criteria: * medically unstable * have a deteriorating condiction * too critically ill to participate
functional inspiratory muscle training in patients diagnosed with hypertension

Conditions: Hypertension,Essential

Summary: this study was planned to investigate the effectiveness of combined exercise training, that is, functional inspiratory muscle training, with breathing exercises to be applied with a portable, easy-to-use respiratory muscle strengthening device, on exercise capacity and peripheral muscle strength.

forty-five individuals will be randomly divided into three groups: functional imt group (n:15): will receive functional inspiratory muscle training (exercise + 50% of mip) imt group i (n:15): will recieve inspiratory muscle training (50% of mip ) control group (n:15): will recieve breathing exercises training

Eligibility criteria:
inclusion criteria: 1. systolic blood pressure ≥140 mmhg or diastolic blood pressure ≥90 mmhg, 2. it will include both male and female subjects aged ≥18 and \<80 years with a previous diagnosis of essential hypertension. 3. subjects receiving no pharmacological treatment or receiving only thiazide diuretics 4. those with a body mass index \<30 kg/m2 those who engage in \<150 minutes of moderate or intense physical activity per week, according to the 5th international physical activity survey exclusion criteria: 1. blood pressure ≥160 / 100 mmhg 2. severe dyspnea; diabetes; orthopedic, musculoskeletal, or fitness limitations; 3. major physiological crises; 4. a current or past history of deep venous thrombosis; history of myocardial infarction or stroke within the 5th year or 6 months ago; 6. congestive heart therapy; 7. unstable angina; 8. or lung disease of any etiology (including asthma and chronic obstructive pulmonary disease); 9. active smokers 10. patients under 18 years of age 11. pregnant women 12. those with active infection 13. those with known malignancy

Keywords: exercise peripheric muscle strenght inspiratory muscle training high blood pressure functionality
the teleap1 cpap-telemonitoring study

Conditions: Obstructive Sleep Apnea

Summary: teleap1 is a multicenter cohort pilot-study designed to evaluate the impact of a published sfrms/splf cpap-telemonitoring diagnosis/therapeutic algorithm on the cpap-compliance of newly treated patients with obstructive sleep apnea..

continuous positive airway pressure (cpap)-devices can track compliance, but also leaks and residual apnea-hypopnea-index (ahiflow) values. cpap tracking systems seem intuitively useful, but there are few data demonstrating the benefit of such systems in improving cpap-compliance and/or patients quality of life. in 2020, a working group from the société française de recherche et de médecine du sommeil (sfrms) and the société de pneumologie de langue française (splf) have proposed a cpap-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea. in order to describe and evaluate the impact of this sfrms/splf-algorithm (not only on the patient but also on the home care provider activity), a one year multicenter cohort pilot-study (telap1-study) was set up.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * patient newly cpap-treated and eligible for care and for the reimbursement by the french social security rules * signed informed consent exclusion criteria: * previous cpap-treatment * pregnancy * inability to understand the nature and aims of the study or to communicate with the investigator * simultaneous participation in another trial with an exclusion clause to participate in another trial * no affiliation with the french social security regime * loss of personal capacity resulting in state protection * deprivation of liberty by judicial or administrative decision

Keywords: obstructive sleep apnea continuous positive airway pressure, telemedicine covid 19 observance leaks apnea hypopnea index.
eribulin with trastuzumab as first-line therapy for locally recurrent or metastatic her2 positive breast cancer

Conditions: Breast Cancer

Summary: this is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal growth factor receptor (her2) positive breast cancer.


Eligibility criteria:
key inclusion criteria: * age 18 years or older * histologically or cytologically proven adenocarcinoma of the breast * subjects who have locally recurrent or metastatic disease with at least one measurable lesion * her2 positive as determined by score of 3 on immunohistochemistry (ihc) staining or gene amplification by fluorescence in situ hybridization (fish). * eastern cooperative oncology group (ecog) performance status (ps) score of 0, 1 or 2 * at least 12 months since prior neoadjuvant or adjuvant chemotherapy * at least 2 weeks since prior radiotherapy, endocrine therapy, trastuzumab, or lapatinib, with complete recovery from the effects of these interventions * adequate renal function * adequate bone marrow function * adequate liver function * adequate cardiac function key exclusion criteria: * prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic her2 breast cancer. * subjects who have had a prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer * prior exposure to greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than 720 mg/m2 epirubicin * inflammatory breast cancer * prior history of hypertensive crisis or hypertensive encephalopathy * clinically significant cardiovascular impairment * subjects with known central nervous system (cns) disease are not eligible, except for those subjects with treated brain metastasis. * subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (ct) or magnetic resonance imaging (mri) * pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen * history of bleeding diasthesis * currently pregnant or breast-feeding. * subjects with preexisting grade 3 or 4 neuropathy. any peripheral neuropathy must recover to grade less than or equal to 2 before enrollment

Keywords: locally recurrent metastatic her2positive breast cancer
phase 2a, exploratory study to evaluate the safety, efficacy, tolerability and pharmacokinetics of xpf-002 in patients with primary/inherited erythromelalgia

Conditions: Primary Erythromelalgia; Inherited Erythromelalgia

Summary: this is a phase 2a single-center, randomized, double-blind, placebo-controlled, parallel group study with xpf-002 applied twice daily over 14 or 21 days in patients with primary/inherited erythromelalgia (iem). the purpose of this study is to determine whether xpf-002 is safe and effective in the treatment of pain caused by iem.

your role in the study would include: * travelling to the clinic (in anniston, alabama, usa) for 3 out-patient visits, each lasting approximately 1 day * travelling and staying in the clinic for 2 in-patient stays: * for the first in-patient visit you will have to spend 8 days and 7 nights in the clinic * for the second in-patient visit you will have to spend 2 days and 1 night in the clinic you can bring books, laptops and dvds to the clinic. if you do not live within driving distance to the clinic you will need to stay in the local area (in anniston, at a local hotel) for 1 to 2 weeks while you use the ointment, in addition to the in-patient portion of the study.

Eligibility criteria:
inclusion criteria: * must have a body mass index (bmi) of 18-40 kg/m2 (inclusive) * have primary or inherited erythromelalgia (iem) * experience flares of pain in your feet or hands caused by erythromelalgia * be generally healthy (apart from your pain) * stop taking your usual pain medications and certain other medications for up to 11.5 weeks * not be pregnant or breast-feeding * must be able and willing to provide informed consent and willing to comply with all study procedures and restrictions exclusion criteria: * must not be in constant pain (must not continually be in moderate pain, 3/10 or more) * coexistent source of pain from other conditions that may interfere with the study interpretation * hiv, hepatitis b or c * treatment for significant depression within 6 months of screening * not willing to use adequate contraception * alcoholism, alcohol or substance abuse * presence or history of major psychiatric disturbance * any other condition or finding that may pose undue risk for participation * use of any other investigational drug in the 30 days prior to dosing * donation or loss of whole blood or plasma prior to dosing as follows: 50 ml to 499 ml within 30 days, or more than 499 ml within 56 days * employee or relative of an employee who is directly involved in the study

Keywords: iem em erythromelalgia erythermalgia red neuralgia peripheral vascular disease vascular disease cardiovascular disease
to research the relation between neonatal morbidities and poor outcome in preterm infants

Conditions: Preterm Infant; Morbidity;Infant; Outcome, Fatal

Summary: from november 2014 to october 2015, a multi-centers retrospective study was conducted to collect compliance, and 8 three-level hospitals from china were included. the infants survived to a postmenstrual age of 36 week with birth weight less than 1500g and without congenital disease. the birth weight, gestational age, morbidities and poor outcomes( death, cerebral palsy, cognitive, et al) were recorded. data were analyzed with chi-square test to observe the relationship between morbidities and poor outcomes. and the predictive effect on the number of the top three morbidities were analyzed by logistic regression analysis.


Eligibility criteria:
inclusion criteria: from november 2014 to october 2015, a multi-centers retrospective study was conducted to collect compliance, and 8 three-level hospitals from china were included. the infants survived to a postmenstrual age of 36 week with birth weight less than 1500g. exclusion criteria: the very low birth weight infants didn't have any congenital disease.
use of baricitenib to maintain of remission

Conditions: Lupus or SLE; Nephritis

Summary: baricitinib a selective janus kinase (jak) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (sle), also known baricitinib, a jak inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no jak inhibitor studies have been conducted in lupus nephritis (ln) maintain remission to date.

baricitinib a selective janus kinase (jak) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (sle), also known baricitinib, a jak inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no jak inhibitor studies have been conducted in lupus nephritis (ln) maintain remission to date. objectives: to assess the efficacy and safety of baricitinib in patients (pts) with ln by dose 4mg versus 2 mg versus mmf 1 gm daily dose.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of lupus nephritis disease * must be able to swallow tablets * lupus nephritis in remission exclusion criteria: * antiphospholipid syndrome disease * thrombosis history * sever anemia, leukopenia or thrombocytopenia * impaired liver and renal function
development and validation of a preoperative frailty index using health administrative data

Conditions: Frail Elderly Syndrome; Surgery; Outcomes; Predictive Value of Tests

Summary: the investigators will create a frailty index using health administrative data available for older people having surgery. the index will be based on the canadian study of health and aging frailty index and standard recommendations for creation of frailty indices.

the investigators will create a frailty index using health administrative data available for older people having surgery. the index will be based on the canadian study of health and aging frailty index and standard recommendations for creation of frailty indices. once derived the index will be tested to measure its association with outcomes, as well as its discrimination. various representations of the frailty index will be tested (primary-as a continuous measure; secondary as a binary, categorical and fractional polynomial variable). performance in subgroups will also be evaluated,

Eligibility criteria:
inclusion criteria: * having elective or emergency noncardiac surgery exclusion criteria: * no provincial health insurance number
health effects of a nordic diet rich in plant-based foods and fish

Conditions: Prehypertension; Hypertension

Summary: the purpose of this study is to investigate the effects of a nordic diet rich in plant-based foods and fish on indicators of cardiovascular disease risk at two different levels of salt intake. the study is a 20-wk randomized controlled crossover trial. the subjects follow a salt-restricted diet during the study. the study begins with a 4-wk run-in phase for all subjects. after that the subjects are randomly allocated to one of two groups. group 1 consumes a healthy nordic low-salt diet enriched with plant-based foods and fish for 16 weeks. group 2 consumes a low-salt diet for 16 weeks. during the 16 weeks, both groups receive salt and placebo capsules in a double-blind, crossover fashion (8+8 weeks).


Eligibility criteria:
inclusion criteria: * prehypertension or hypertension (systolic blood pressure 130-159 mmhg or diastolic blood pressure 85-99 mmhg) exclusion criteria: * smoking * regular use of medications * intestinal disorders * symptomatic cardiovascular disease * obesity (bmi\>35 kg/m2) * vegetarianism * high intake of alcohol * allergy to fish * pregnancy

Keywords: human clinical trial dietary intervention study blood pressure cardiovascular biomarkers nutritional biomarkers gene expression
efficacy of ultrasound guided rectus sheath block on post operative quality of recovery

Conditions: Postoperative Pain

Summary: effective postoperative pain management following laparotomy represents a cornerstone in the care of surgical patients. with the growing utilization of enhanced recovery after surgery protocols (eras), a paradigm shift in perioperative care has resulted in reduction of both hospital stay and clinical complications faced by patients. one important component of successful implementation of eras protocol is optimized pain control. it has been shown that opioids have a considerable role in reducing bowel motility in addition; it hinders early mobilization and enteral feeding besides their commonly faced side effects such as nausea and vomiting. consequently, eras programs encourage the usage of multimodal opioid sparing analgesia which includes neuraxial or regional anesthesia techniques to provide effective pain relief while reducing the opioid related side effects. \[1\] regional blocks have remained popular with evidence of superior postoperative pain control when compared with systemic analgesics. regional anaesthesia techniques have undergone considerable refinement with the advent of ultrasound guidance. ultrasound visualization of anatomical structures increases both the safety and quality of regional blocks through optimal needle placement. ultrasound-guided rectus sheath (rs) blocks are an emerging anaesthetic technique providing excellent analgesia after laparotomy. the anatomic characteristics of this block suggest minimal serious complications are likely, and this regional block is particularly useful where epidural is contraindicated


Eligibility criteria:
inclusion criteria: 1. 18-60 years old patients 2. asa 1-2 patients 3. patients undergoing elective midline laparotomy. exclusion criteria: * 1. refusal to consent, 2. previous laparotomy (subsequently amended to exclude only a laparotomy with a paramedian scar), 3. significant hepatic or renal disease, 4. any condition limiting the use of co-analgesics (diclofenac and acetaminophen), 5. coagulopathy (international normalized ratio: 1.5 ) 6. patients with body weight \\ 50 kg.
a study to investigate dosage, effectiveness, and safety of perampanel when used as first add-on therapy in participants >=12 years with partial onset seizures with or without secondary generalization or with primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy

Conditions: Idiopathic Generalized Epilepsy; Partial Onset Seizures; Generalised Tonic-Clonic Seizures

Summary: the primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures \[pos\] with or without secondary generalization \[sg\] or for primary generalized tonic-clonic seizures \[pgtcs\] associated with idiopathic generalized epilepsy \[ige\] as first adjunctive to antiepileptic drug (aed) monotherapy as part of their routine clinical care.


Eligibility criteria:
inclusion criteria: 1. diagnosis of epilepsy 2. history of pos with or without sg or pgtcs associated with ige 3. documented pos with or without sg or pgtcs associated with ige, within the past 12 months 4. previously treated with 1 or 2 aeds as monotherapy 5. at least 4 weeks' seizure diary data, or sufficient clinical detail to calculate baseline seizure frequency exclusion criteria: 1. episode(s) of status epilepticus within the past 6 months before screening 2. previously treated with 2 or more aeds in combination (other than during cross-titration between aed monotherapies) 3. previous or current use of perampanel note: retrospective inclusions will be allowed but only if the time between the initiation of perampanel treatment and the inclusion does not exceed 7 calendar days 4. hypersensitivity to perampanel or any of the excipients

Keywords: perampanel fycompa epilepsy seizures prospective